Moluzen Molnupiravir 200 mg is an oral antiviral recently approved for the treatment of mild to moderate COVID-19 infections. Designed to inhibit the replication of the SARS-CoV-2 virus, it mimics natural nucleosides and causes a buildup of mutations in viral RNA—a process known as “error...